Mouse induced glioma-initiating cell models and therapeutic targets

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 6, 2010, Pages 471-480

  Kondo, Toru ^a,b  

^a RIKEN Center for Biosystems Dynamics Research   (Japan)

^b EHIME UNIVERSITY   (Japan)

Author keywords

Glioblastoma multiforme (GBM); Glioma initiating cells (GIC); Neural stem cells (NSC); P53; Plagl1; Ras; Sox11

Indexed keywords

CELL SURFACE MARKER; NOTCH RECEPTOR; PROTEIN P53; PROTEIN TYROSINE KINASE; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR SOX11; WNT PROTEIN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INITIATING CELL; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CELL TRANSPLANTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA; GLIOMA INITIATING CELL; HUMAN; IN VIVO STUDY; METASTASIS; NERVE CELL; NERVE CELL DIFFERENTIATION; NONHUMAN; ONCOGENE; ONCOGENE C H RAS; PLAGL1 GENE; PROTEIN EXPRESSION; RETINOBLASTOMA; STEM CELL;

EID: 78649898679     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520611009060471     Document Type: Article

References (106)

1. Weissman, I.L.; Anderson, D.J.; Gage, F. Stem and progenitorcells: origins, phenotypes, lineage commitments, and transdifferentiations.Annu. Rev. Cell Dev. Biol., 2001, 17, 387-403.
2. Gage, F. Mammalian neural stem cells. Science, 2000, 287, 1433-1438.
3. Singh, S.K.; Clarke, I.D.; Hide, T.; Dirks, P.B. Cancer stem cells innervous system tumors. Oncogene, 2004, 23, 7267-7273.
4. Kondo, T. Brain cancer stem-like cells. Eur. J. Cancer, 2006, 42, 1237-1242.
5. Vescovi, A.L.; Galli, R.; Reynolds, B.A. Brain tumour stem cells.Nat. Rev. Cancer, 2006, 6, 425-436.
6. Bachoo, R.M.; Maher, E.A.; Ligon, K.L.; Sharpless, N.E.; Chan, S.S.; You, M.J.; Tang, Y.; DeFrances, J.; Stover, E.; Weissleder, R.; Rowitch, D.H.; Louis, D.N.; DePinho, R.A. Epidermal growthfactor receptor and Ink4a/Arf: convergent mechanisms governingterminal differentiation and transformation along the neural stemcell to astrocyte axis. Cancer Cell, 2002, 1, 267-277.
7. Dai, C.; Celestino, J.C.; Okada, Y.; Louis, D.N.; Fuller, G.N.; Holland, E.C. PDGF autocrine stimulation dedifferentiates culturedastrocytes and induces oligodendrogliomas and oligoastrocytomasfrom neural progenitors and astrocytes in vivo. Genes Dev., 2001, 15, 1913-1925.
8. Uhrbom, L.; Dai, C.; Celestino, J.C.; Rosenblum, M.K.; Fuller, G.N.; Holland, E.C. Ink4a-Arf loss cooperates with KRas activationin astrocytes and neural progenitors to generate glioblastomasof various morphologies depending on activated Akt. Cancer Res., 2002, 62, 5551-5558.
9. Doetsch, F.; Caille, I.; Lim, D.A.; Garcia-Verdugo, J.M.; Alvarez-Buylla, A. Subventricular zone astrocytes are neural stem cells inthe adult mammalian brain. Cell, 1999, 97, 703-716.
10. Kondo, T.; Raff, M. Oligodendrocyte precursor cells reprogrammedto become multipotential CNS stem cells. Science, 2000, 289, 1754-1757.
11. Laywell, E.D.; Rakic, P.; Kukekov, V.G.; Holland, E.C.; Steindler, D.A. Identification of a multipotent astrocytic stem cell in the immatureand adult mouse brain. Proc. Natl. Acad. Sci. USA, 2000, 97, 13889-13894.
12. Belachew, S.; Chittajallu, R.; Aguirre, A.A.; Yuan, X.; Kirby, M.; Anderson, S.; Gallo, V. Postnatal NG2 proteoglycan-expressingprogenitor cells are intrinsically multipotent and generate functionalneurons. J. Cell Biol., 2003, 161, 169-186.
13. Nunes, M.C.; Roy, N.S.; Keyoung, H.M.; Goodman, R.R.; McKhann, II G.; Jiang, L.; Kang, J.; Nedergaard, M.; Goldman, S.A. Identification and isolation of multipotential neural progenitorcells from the subcortical white matter of the adult human brain.Nat. Med., 2003, 9, 439-447.
14. Globus, J.H.; Kuhlenbeck, H. The subependymal cell plate (matrix)and its relationship to brain tumors of the ependymal type. J. Neuropathol.Exp. Neurol., 1944, 3, 1-35.
15. Hopewell, J.W.; Wright, E.A. The importance of implantation sitein cerebral carcinogenesis in rats. Cancer Res., 1969, 29, 1927-1932.
16. Copeland, D.D.; Vogel, F.S.; Bigner, D.D. The induction of intracranialneoplasms by the inoculation of avian sarcoma virus in perinataland adult rats. J. Neuropathol. Exp. Neurol., 1975, 34, 340-358.
17. Wulf, G.G.; Wang, R.Y.; Kuehnle, I.; Weidner, D.; Marini, F.; Brenner, M.K.; Andreeff, M.; Goodell, M.A. A leukemic stem cellwith intrinsic drug efflux capacity in acute myeloid leukemia.Blood, 2001, 98, 1166-1173.
18. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance incancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2002, 2, 48-58.
19. Goodell, M.A.; Brose, K.; Paradis, G.; Conner, A.S.; Mulligan, R.C. Isolation and functional properties of murine hematopoieticstem cells that are replicating in vivo. J. Exp. Med., 1996, 183, 1797-1806.
20. Zhou, S.; Schuetz, J.D.; Bunting, K.D.; Colapietro, A.M., Sampath, J.; Morris, J.J.; Lagutina, I.; Grosveld, G.C.; Osawa, M.; Nakauchi, H.; Sorrentino, B.P. The ABC transporter Bcrp1/ABCG2 is expressedin a wide variety of stem cells and is a molecular determinantof the side-population phenotype. Nat. Med., 2001, 7, 1028-1034.
21. Mitsutake, N.; Iwao, A.; Nagai, K.; Namba, H.; Ohtsuru, A.; Saenko, V.; Yamashita, S. Characterization of side population inthyroid cancer cell lines: cancer stem-like cells are enriched partlybut not exclusively. Endocrinology, 2007, 148, 1797-1803.
22. Shmelkov, S.V.; Butler, J.M.; Hooper, A.T.; Hormigo, A.; Kushner, J.; Milde, T.; St Clair, R.; Baljevic, M.; White, I.; Jin, D.K.; Chadburn, A.; Murphy, A.J.; Valenzuela, D.M.; Gale, N.W.; Thurston, G.; Yancopoulos, G.D.; D'Angelica, M.; Kemeny, N.; Lyden, D.; Rafii, S. CD133 expression is not restricted to stemcells, and both CD133+ and CD133- metastatic colon cancer cellsinitiate tumors. J. Clin. Invest., 2008, 118, 2111-2120.
23. Krivtsov, A.V.; Armstrong, S.A. MLL translocations, histonemodifications and leukaemia stem-cell development. Nat. Rev.Cancer, 2007, 7, 823-833.
24. Cancer Genome Atlas Research Network. Comprehensive genomiccharacterization defines human glioblastoma genes and core pathways.Nature, 2008, 455, 1061-1068.
25. Parsons, D.W.; Jones, S.; Zhang, X.; Lin, J.C.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.M.; Gallia, G.L.; Olivi, A.; McLendon, R.; Rasheed, B.A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D.A.; Tekleab, H.; Diaz, L.A. Jr.; Hartigan, J.; Smith, D.R.; Strausberg, R.L.; Marie, S.K.; Shinjo, S.M.; Yan, H.; Riggins, G.J.; Bigner, D.D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V.E.; Kinzler, K.W. An integratedgenomic analysis of human glioblastoma multiforme. Science, 2008, 321, 1807-1812.
26. Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature, 2001, 414, 105-111.
27. Katsetos, C.D.; Spandou, E.; Legido, A.; Taylor, M.L.; Zanelli, S.A.; de Chadarevian, J.P.; Christakos, S.; Mishra, O.P.; Delivoria-Papadopoulos, M. Localization of the neuronal class III betatubulinin oligodendrogliomas: comparison with Ki-67 proliferativeindex and 1p/19q status. J. Neuropathol. Exp. Neurol., 2001, 61, 307-320.
28. Toda, M.; Iizuka, Y.; Yu, W.; Imai, T.; Ikeda, E.; Yoshida, K.; Kawase, T.; Kawakami, Y.; Okano, H.; Uyemura, K. Expression of the neural RNA-binding protein Musashi1 in human gliomas. Glia, 2001, 34, 1-7.
29. Ligon, K.L.; Huillard, E.; Mehta, S.; Kesari, S.; Liu, H.; Alberta, J.A.; Bachoo, R.M.; Kane, M.; Louis, D.N.; DePinho, R.A.; Anderson, D.J.; Stiles, C.D.; Rowitch, D.H. Olig2-regulated lineagerestrictedpathway controls replication competence in neural stemcells and malignant glioma. Neuron, 2007, 53, 503-517.
30. Barnett, S.C.; Robertson, L.; Graham, D.; Allan, D.; Rampling, R.Oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells transformedwith c-myc and H-ras form high-grade glioma after stereotacticinjection into the rat brain. Carcinogenesis, 1998, 19, 1529-1537.
31. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance incancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2002, 2, 48-58.
32. Szakacs, G.; Paterson, J.K.; Ludwig, J.A.; Booth-Genthe, C.; Gottesman, M.M. Targeting multidrug resistance in cancer. Nat.Rev. Drug Discov., 2006, 5, 219-234.
33. Bao, S.; Wu, Q.; McLendon, R.E.; Hao, Y.; Shi, Q.; Hjelmeland, A.B.; Dewhirst, M.W.; Bigner, D.D.; Rich, J.N. Glioma stem cellspromote radioresistance by preferential activation of the DNAdamage response. Nature, 2006, 444, 756-760.
34. Liu, G.; Yuan, X.; Zeng, Z.; Tunici, P.; Ng, H.; Abdulkadir, I.R.; Lu, L.; Irvin, D.; Black, K.L.; Yu, J.S. Analysis of gene expressionand chemoresistance of CD133+ cancer stem cells in glioblastoma.Mol. Cancer, 2006, 5, 67-78.
35. Hermann, P.C.; Huber, S.L.; Herrler, T.; Aicher, A.; Ellwart, J.W.; Guba, M.; Bruns, C.J.; Heeschen, C. Distinct populations of cancerstem cells determine tumor growth and metastatic activity in humanpancreatic cancer. Cell Stem Cell, 2007, 1, 313-323.
36. Li, L.; Neaves, W.B. Normal stem cells and cancer stem cells: Theniche matters. Cancer Res., 2006, 66, 4553-4557.
37. Moore, K.A.; Lemischka, I.R. Stem cells and their niches. Science, 2006, 311, 1880-1885.
38. Das, B.; Tsuchida, R.; Malkin, D.; Koren, G.; Baruchel, S.; Yeger, H. Hypoxia enhances tumor stemness by increasing the invasiveand tumorigenic side population fraction. Stem Cells, 2008, 26, 1818-1830.
39. Matsumoto, K.; Arao, T.; Tanaka, K.; Kaneda, H.; Kudo, K.; Fujita, Y.; Tamura, D.; Aomatsu, K.; Tamura, T.; Yamada, Y.; Saijo, N.; Nishio, K. mTOR signal and hypoxia-inducible factor-1 alpharegulate CD133 expression in cancer cells. Cancer Res., 2009, 69, 7160-7164.
40. Kaplan, R.N.; Riba, R.D.; Zacharoulis, S.; Bramley, A.H.; Vincent, L.; Costa, C.; MacDonald, D.D.; Jin, D.K.; Shido, K.; Kerns, S.A.; Zhu, Z.; Hicklin, D.; Wu, Y.; Port, J.L.; Altorki, N.; Port, E.R.; Ruggero, D.; Shmelkov, S.V.; Jensen, K.K.; Rafii, S.; Lyden, D.VEGFR1-positive haematopoietic bone marrow progenitors initiatethe pre-metastatic niche. Nature, 2005, 438, 820-827.
41. Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.; Caceres-Cortes, J.; Minden, M.; Paterson, B.; Caligiuri, M.A.; Dick, J.E. A cell initiating human acute myeloid leukaemia aftertransplantation into SCID mice. Nature, 1994, 367, 645-648.
42. Bonnet, D.; Dick, J.E. Human acute myeloid leukemia is organizedas a hierarchy that originates from a primitive hematopoietic cell.Nat. Med., 1997, 3, 730-737.
43. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast cancercells. Proc. Natl. Acad. Sci. USA, 2003, 100, 3983-3988.
44. Ponti, D.; Costa, A.; Zaffaroni, N.; Pratesi, G.; Petrangolini, G.; Coradini, D.; Pilotti, S.; Pierotti, M.A.; Daidone, M.G. Isolationand in vitro propagation of tumorigenic breast cancer cells withstem/progenitor cell properties. Cancer Res., 2005, 65, 5506-5511.
45. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B. Identificationof human brain tumour initiating cells. Nature, 2004, 432, 396-401.
46. O'brien, C.A.; Pollett, A.; Gallinger, S.; Dick, J.E. A human coloncancer cell capable of initiating tumour growth in immunodeficientmice. Nature, 2007, 445, 106-110.
47. Ricci-Vitiani, L., Lombardi, D.G., Pilozzi, E.; Biffoni, M.; Todaro, M.,; Peschle, C.; De Maria, R. Identification and expansion of humancolon-cancer-initiating cells. Nature, 2007, 445, 111-115.
48. Collins, A.T., Berry, P.A., Hyde, C.; Stower, M.J.; Maitland, N.J.Prospective identification of tumorigenic prostate cancer stem cells.Cancer Res., 2005, 65, 10946-10951.
49. Read, T.A.; Fogarty, M.P.; Markant, S.L.; McLendon, R.E.; Wei, Z.; Ellison, D.W.; Febbo, P.G.; Wechsler-Reya, R.J. Identificationof CD15 as a marker for tumor-propagating cells in a mouse modelof medulloblastoma. Cancer Cell, 2009, 15, 135-147.
50. Son, M.J.; Woolard, K.; Nam, D.H.; Lee, J.; Fine, H.A. SSEA-1 isan enrichment marker for tumor-initiating cells in human glioblastoma.Cell Stem Cell, 2009, 4, 440-452.
51. Ward, R.J.; Lee, L.; Graham, K.; Satkunendran, T.; Yoshikawa, K.; Ling, E.; Harper, L.; Austin, R.; Nieuwenhuis, E.; Clarke, I.D.; Hui, C.C.; Dirks, P.B. Multipotent CD15+ cancer stem cells inpatched-1-deficient mouse medulloblastoma. Cancer Res., 2009, 69, 4682-4690.
52. Morita, Y.; Ema, H.; Yamazaki, S.; Nakauchi, H. Non-sidepopulationhematopoietic stem cells in mouse bone marrow. Blood, 2006, 108, 2850-2856.
53. Hirschmann-Jax, C., Foster, A.E., Wulf, G.G.; Nuchtern, J.G.; Jax, T.W.; Gobel, U.; Goodell, M.A.; Brenner, M.K. A distinct "sidepopulation" of cells with high drug efflux capacity in human tumorcells. Proc. Natl. Acad. Sci. USA, 2004, 101, 14228-14233.
54. Kondo, T.; Setoguchi, T.; Taga, T. Persistence of a small subpopulationof cancer stem-like cells in the C6 glioma cell line. Proc.Natl. Acad. Sci. USA, 2004, 101, 781-786.
55. Patrawala, L.; Calhoun, T.; Schneider-Broussard, R.; Zhou, J.; Claypool, K.; Tang, D.G. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancercells are similarly tumorigenic. Cancer Res., 2005, 65, 6207-6219.
56. Ponti, D.; Costa, A.; Zaffaroni, N.; Pratesi, G.; Petrangolini, G.; Coradini, D.; Pilotti, S.; Pierotti, M.A.; Daidone, M.G. Isolationand in vitro propagation of tumorigenic breast cancer cells withstem/progenitor cell properties. Cancer Res., 2005, 65, 5506-5511.
57. Haraguchi, N.; Utsunomiya, T.; Inoue, H.; Tanaka, F.; Mimori, K.; Barnard, G.F.; Mori, M. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cell, 2006, 24, 506-513.
58. Szotek, P.P.; Pieretti-Vanmarcke, R.; Masiakos, P.T.; Dinulescu, D.M.; Connolly, D.; Foster, R.; Dombkowski, D.; Preffer, F.; Maclaughlin, D.T.; Donahoe, P.K. Ovarian cancer side population definescells with stem cell-like characteristics and Mullerian InhibitingSubstance responsiveness. Proc. Natl. Acad. Sci. USA, 2006, 103, 11154-11159.
59. Jones, R.J.; Barber, J.P.; Vala, M.S.; Collector, M.I.; Kaufmann, S.H.; Ludeman, S.M.; Colvin, O.M.; Hilton, J. Assessment of aldehydedehydrogenase in viable cells. Blood, 1995, 85, 2742-2746.
60. Cai, J.; Cheng, A.; Luo, Y.; Lu, C.; Mattson, M.P.; Rao, M.S.; Furukawa, K. Membrane properties of rat embryonic multipotentneural stem cells. J. Neurochem., 2004, 88, 212-226.
61. Pearce, D.J.; Taussig, D.; Simpson, C.; Allen, K.; Rohatiner, A.Z.; Lister, T.A.; Bonnet, D. Characterization of cells with a high aldehydedehydrogenase activity from cord blood and acute myeloidleukemia samples. Stem Cells, 2005, 23, 752-760.
62. Ginestier, C.; Hur, M.H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C.G.; Liu, S.; Schott, A.; Hayes, D.; Birnbaum, D.; Wicha, M.S.; Dontu, G.ALDH1 is a marker of normal and malignant human mammarystem cells and a predictor of poor clinical outcome. Cell Stem Cell, 2007, 1, 555-567.
63. Korkaya, H.; Paulson, A.; Iovino, F.; Wicha, M.S. HER2 regulatesthe mammary stem/progenitor cell population driving tumorigenesisand invasion. Oncogene, 2008, 27, 6120-6130.
64. Pollard, S.M.; Yoshikawa, K.; Clarke, I.D.; Danovi, D.; Stricker, S.; Russell, R.; Bayani, J.; Head, R.; Lee, M.; Bernstein, M.; Squire, J.A.; Smith, A.; Dirks, P. Glioma stem cell lines expandedin adherent culture have tumor-specific phenotypes and are suitablefor chemical and genetic screens. Cell Stem Cell, 2009, 4, 568-580.
65. Toledo, F.; Wahl, G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer, 2006, 6, 909-923.
66. Kleihues, P.; Ohgaki, H. Primary and secondary glioblastoma: fromconcept to clinical diagnosis. Neuro-Oncol, 1999, 1, 44-51.
67. Reifenberger, G.; Liu, L.; Ichimura, K.; Schmidt, E.E.; Collins, V.P. Amplification and overexpression of the MDM2 gene in asubset of human malignant gliomas without p53 mutations. CancerRes., 1993, 53, 2736-2739.
68. Bagchi, A.; Papazoglu, C.; Wu, Y.; Capurso, D.; Brodt, M.; Francis, D.; Bredel, M.; Vogel, H.; Mills, A.A. CHD5 is a tumorsuppressor at human 1p36. Cell, 2007, 128, 459-475.
69. Classon, M.; Harlow, E. The retinoblastoma tumour suppressor indevelopment and cancer. Nat. Rev. Cancer, 2002, 2, 910-917.
70. Schmidt, E.E.; Ichimura, K.; Reifenberger, G.; Collins, V.P.CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occursin the majority of glioblastomas. Cancer Res., 1994, 54, 6321-6324.
71. Schubbert, S.; Shannon, K.; Bollag, G. Hyperactive Ras in developmentaldisorders and cancer. Nat. Rev. Cancer, 2007, 7, 295-308.
72. Duerr, E.M.; Rollbrocker, B.; Hayashi, Y.; Peters, N.; Meyer-Puttlitz, B.; Louis, D.N.; Schramm, J.; Wiestler, O.D.; Parsons, R.; Eng, C.; von Deimling, A. PTEN mutations in gliomas and glioneuronal tumors. Oncogene, 1998, 16, 2259-2264.
73. Radtke, F.; Raj, K. The role of Notch in tumorigenesis: oncogeneor tumour suppressor? Nat. Rev. Cancer, 2003, 3, 756-767.
74. Fan, X.; Khaki, L.; Zhu, T.S.; Soules, M.E.; Talsma, C.E,; Gul, N.; Koh, C.; Zhang, J.; Li, Y.M.; Maciaczyk, J.; Nikkhah, G.; Dimeco, F.; Piccirillo, S.; Vescovi, A.L.; Eberhart, C.G. NOTCH pathwayblockade depletes CD133-positive glioblastoma cells and inhibitsgrowth of tumor neurospheres and xenografts. Stem Cells, 2010, 28, 5-16.
75. Wang, J.; Wakeman, T.P.; Lathia, J.D.; Hjelmeland, A.B.; Wang, X.F.; White, R.R.; Rich, J.N.; Sullenger, B.A. Notch promotes radioresistanceof glioma stem cells. Stem Cells, 2010, 28, 17-28.
76. Krebs, L.T.; Xue, Y.; Norton, C.R.; Shutter, J.R.; Maguire, M.; Sundberg, J.P.; Gallahan, D.; Closson, V.; Kitajewski, J.; Callahan, R.; Smith, G.H.; Stark, K.L.; Gridley, T. Notch signaling is essentialfor vascular morphogenesis in mice. Genes Dev., 2000, 14, 1343-1352.
77. Swiatek, P.J.; Lindsell, C.E.; del Amo, F.F.; Weinmaster, G.; Gridley, T. Notch1 is essential for postimplantation development inmice. Genes Dev., 1994, 8, 707-719.
78. Xue, Y.; Gao, X.; Lindsell, C.E.; Norton, C.R.; Chang, B.; Hicks, C.; Gendron-Maguire, M.; Rand, E.B.; Weinmaster, G.; Gridley, T.Embryonic lethality and vascular defects in mice lacking the Notchligand Jagged1. Hum. Mol. Genet., 1999, 8, 723-730.
79. Logan, C.Y.; Nusse, R. The Wnt signaling pathway in developmentand disease. Annu. Rev. Cell Dev. Biol., 2004, 20, 781-810.
80. Moon, R.T., Kohn, A.D., De Ferrari, G.V.; Kaykas, A. WNT and beta-catenin signalling: diseases and therapies. Nat. Rev. Genet., 2004, 5, 691-701.
81. Reya, T.; Clevers, H. Wnt signalling in stem cells and cancer.Nature, 2005, 434, 843-850.
82. Ikeya, M.; Lee, S.M.; Johnson, J.E.; McMahon, A.P.; Takada, S.Wnt signalling required for expansion of neural crest and CNS progenitors.Nature, 1997, 389, 966-970.
83. Chenn, A.; Walsh, C.A. Regulation of cerebral cortical size bycontrol of cell cycle exit in neural precursors. Science, 2002, 297, 365-369.
84. Lee, S.M.K.; Tole, S.; Grove, E.; McMahon, A.P. A local Wnt-3asignal is required for development of the mammalian hippocampus.Development, 2000, 197, 457-467.
85. McMahon, A.P.; Bradley, A. The Wnt-1 (int-1) proto-oncogene isrequired for development of a large region of the mouse brain. Cell, 1990, 62, 1073-1085.
86. Zurawel, R.H., Chiappa, S.A., Allen, C.; Raffel, C. Sporadic medulloblastomascontain oncogenic beta-catenin mutations. CancerRes., 1998, 58, 896-899.
87. Dahmane, N.; Sanchez, P.; Gitton, Y.; Palma, V.; Sun, T.; Beyna, M.; Weiner, H.; Ruiz i Altaba, A. The Sonic Hedgehog-Gli pathwayregulates dorsal brain growth and tumorigenesis. Development, 2001, 128, 5201-5212.
88. Ruiz i Altaba, A.; Palma, V.; Dahmane, N. Hedgehog-Gli signallingand the growth of the brain. Nat. Rev. Neurosci., 2002, 3, 24-33.
89. Pasca di Magliano, M.; Hebrok, M. Hedgehog signalling in cancerformation and maintenance. Nat. Rev. Cancer, 2003, 3, 903-911.
90. Ding, Q.; Motoyama, J.; Gasca, S.; Mo, R.; Sasaki, H.; Rossant, J.; Hui, C.C. Diminished Sonic hedgehog signaling and lack of floorplate differentiation in Gli2 mutant mice. Development, 1998, 125, 2533-2543.
91. Matise, M.P.; Epstein, D.J.; Park, H.L.; Platt, K.A.; Joyner, A.L.Gli2 is required for induction of floor plate and adjacent cells, butnot most ventral neurons in the mouse central nervous system.Development, 1998, 125, 2759-2770.
92. Park, H.L.; Bai, C.; Platt, K.A.; Matise, M.P.; Beeghly, A.; Hui, C.C.; Nakashima, M.; Joyner, A.L. Mouse Gli1 mutants are viablebut have defects in SHH signaling in combination with a Gli2 mutation.Development, 2000, 127, 1593-1605.
93. Palma, V.; Ruiz i Altaba, A. Hedgehog-GLI signaling regulates thebehavior of cells with stem cell properties in the developing neocortex.Development, 2004, 131, 337-345.
94. Machold, R.; Hayashi, S.; Rutlin, M.; Muzumdar, M.D.; Nery, S.; Corbin, J.G.; Gritli-Linde, A.; Dellovade, T.; Porter, J.A.; Rubin, L.L.; Dudek, H.; McMahon, A.P.; Fishell, G. Sonic hedgehog isrequired for progenitor cell maintenance in telencephalic stem cellniches. Neuron, 2003, 39, 937-950.
95. Goodrich, L.V., Milenkovic, L., Higgins, K.M.; Scott, M.P. Alteredneural cell fates and medulloblastoma in mouse patched mutants.Science, 1997, 277, 1109-1113.
96. Berman, D.M.; Karhadkar, S.S.; Hallahan, A.R.; Pritchard, J.I.; Eberhart, C.G.; Watkins, D.N.; Chen, J.K.; Cooper, M.K.; Taipale, J.; Olson, J.M.; Beachy, P.A. Medulloblastoma growth inhibitionby hedgehog pathway blockade. Science, 2002, 297, 1559-1561.
97. Cozzio, A.; Passegué, E.; Ayton, P.M.; Karsunky, H.; Cleary, M.L.; Weissman, I.L. Similar MLL-associated leukemias arisingfrom self-renewing stem cells and short-lived myeloid progenitors.Genes Dev., 2003, 17, 3029-3035.
98. Huntly, B.J.; Shigematsu, H.; Deguchi, K.; Lee, B.H.; Mizuno, S.; Duclos, N.; Rowan, R.; Amaral, S.; Curley, D.; Williams, I.R.; Akashi, K.; Gilliland, D.G. MOZ-TIF2, but not BCR-ABL, confersproperties of leukemic stem cells to committed murine hematopoieticprogenitors. Cancer Cell, 2004, 6, 587-596.
99. Krivtsov, A.V.; Twomey, D.; Feng, Z.; Stubbs, M.C.; Wang, Y.; Faber, J.; Levine, J.E.; Wang, J.; Hahn, W.C.; Gilliland, D.G.; Golub, T.R.; Armstrong, S.A. Transformation from committedprogenitor to leukaemia stem cell initiated by MLL-AF9. Nature, 2006, 442, 324-331.
100. Ligon, K.L.; Huillard, E.; Mehta, S.; Kesari, S.; Liu, H.; Alberta, J.A.; Bachoo, R.M.; Kane, M.; Louis, D.N.; Depinho, R.A.; Anderson, D.J.; Stiles, C.D.; Rowitch, D.H. Olig2-regulated lineagerestrictedpathway controls replication competence in neural stemcells and malignant glioma. Neuron, 2007, 53, 503-517.
101. Hide, T.; Takezaki, T.; Nakatani, Y.; Nakamura, H.; Kuratsu, J.; Kondo, T. Sox11 prevents tumorigenesis of glioma-initiating cellsby inducing neuronal differentiation. Cancer Res., 2009, 15, 7953-7959.
102. Bergsland, M.; Werme, M.; Malewicz, M.; Perlmann, T.; Muhr, J.The establishment of neuronal properties is controlled by Sox4 and Sox11. Genes Dev., 2006, 20, 3475-3486.
103. Madhavan, S.; Zenklusen, J.C.; Kotliarov, Y.; Sahni, H.; Fine, H.A.; Buetow, K. Rembrandt: helping personalized medicine becomea reality through integrative translational research. Mol.Cancer Res., 2009, 7, 157-167.
104. Valente, T.; Junyent, F.; Auladell, C. Zac1 is expressed in progenitor/stem cells of the neuroectoderm and mesoderm during embryogenesis: differential phenotype of the Zac1-expressing cells duringdevelopment. Dev. Dyn., 2005, 233, 667-679.
105. Van Dyck, F.; Declercq, J.; Braem, C.V.; Van de Ven, W.J. PLAG1, the prototype of the PLAG gene family: versatility in tumourdevelopment (review). Int. J. Oncol., 2007, 30, 765-774.
106. Varrault, A.; Gueydan, C.; Delalbre, A.; Bellmann, A.; Houssami, S.; Aknin, C.; Severac, D.; Chotard, L.; Kahli, M.; Le Digarcher, A.; Pavlidis, P.; Journot, L. Zac1 regulates an imprinted gene networkcritically involved in the control of embryonic growth. Dev.Cell, 2006, 11, 711-722.